INS and diabetes mellitus: The three diabetes drugs (i.e., empagliflozin, dapagliflozin, and sitagliptin) had a total of 17 comparative studies, but few studies of ibrutinib (n = 6), sacubitril/valsartan (n = 5), and ustekinumab (n = 2) were identified; furthermore, no relevant studies were found for insulin aspart according to the primary search strategy (Table 2).